Department of Urology, The First Affiliated Hospital, Bengbu Medical College, Bengbu, 233030, China.
Clin Transl Oncol. 2013 Oct;15(10):849-54. doi: 10.1007/s12094-013-1014-4. Epub 2013 Feb 14.
MicroRNA-31 (miR-31) has different expression patterns in various human cancers. Especially in urothelial carcinoma of the bladder, it has been demonstrated to be decreased expression in the invasive tumors and homozygously deleted. However, its clinical significance in human bladder cancer has not yet been elucidated. Thus, the purpose of this study was to investigate the diagnostic and prognostic values of miR-31 in this disease.
Expression levels of miR-31 in 126 pairs of bladder cancer and adjacent normal tissues were detected by real-time quantitative RT-PCR assay. To determine its prognostic value, overall survival (OS) and progression-free survival (PFS) were evaluated using the Kaplan-Meier method, and multivariate analysis was performed using the Cox proportional hazard analysis.
MiR-31 expression in bladder cancer tissues was significantly lower than those in adjacent normal tissues (mean expression level: 2.1 ± 0.9 vs. 3.8 ± 1.2, P < 0.001). When categorized into low vs. high expression, low miR-31 expression was negatively associated with the tumor stage (P = 0.02), the status of recurrence (P = 0.01), progression (P = 0.01), and death (P = 0.006) of patients with bladder cancer. Moreover, low miR-31 expression clearly predicted poorer PFS (P = 0.001) and OS (P < 0.001). In the multivariate analysis, low miR-31 expression was an independent prognostic factor for both PFS (P = 0.01) and OS (P = 0.008).
These findings show that miR-31 may contribute to the progression of bladder cancer and its downregulation may be independently associated with unfavorable PFS and OS, suggesting that miR-31 might be a promising marker for further risk stratification in the treatment of this cancer.
MicroRNA-31（miR-31）在各种人类癌症中的表达模式不同。特别是在膀胱癌中，已经证明其在侵袭性肿瘤中表达下调且纯合缺失。然而，其在人类膀胱癌中的临床意义尚未阐明。因此，本研究旨在探讨 miR-31 在这种疾病中的诊断和预后价值。
通过实时定量 RT-PCR 检测 126 对膀胱癌及相邻正常组织中 miR-31 的表达水平。为了确定其预后价值，采用 Kaplan-Meier 法评估总生存期（OS）和无进展生存期（PFS），采用 Cox 比例风险分析进行多因素分析。
膀胱癌组织中 miR-31 的表达明显低于相邻正常组织（平均表达水平：2.1±0.9 对 3.8±1.2，P<0.001）。当分为低表达与高表达时，低 miR-31 表达与肿瘤分期（P=0.02）、患者膀胱癌的复发状态（P=0.01）、进展状态（P=0.01）和死亡状态（P=0.006）呈负相关。此外，低 miR-31 表达明显预示着更差的 PFS（P=0.001）和 OS（P<0.001）。在多因素分析中，低 miR-31 表达是 PFS（P=0.01）和 OS（P=0.008）的独立预后因素。
这些发现表明，miR-31 可能促进膀胱癌的进展，其下调可能与不良的 PFS 和 OS 独立相关，提示 miR-31 可能成为该癌症治疗中进一步风险分层的有前途的标志物。
